CCO Management Series
Understanding and Implementing the AASLD’s 2009 Practice Guidelines* on the Diagnosis, Management, and Treatment of Hepatitis C: An Update
Interactive Virtual Presentations
Hepatitis C Testing and Counseling: the Gateway to Treatment
|
Program Director: Bruce R. Bacon, MD
|
|
David L. Thomas, MD, MPH, discusses how risk-based testing can help identify the large population of undiagnosed patients infected with hepatitis C.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recount the risk factors for HCV infection
- Discuss which populations should be tested for HCV infection
- Explain how HCV-infected persons should be counseled to avoid transmitting HCV to others
- Recall which populations should be tested for HCV antibodies and which should be tested for HCV RNA
|
Slideset: Hepatitis C Testing and Counseling: the Gateway to Treatment
 |
|
In this downloadable slideset, David L. Thomas, MD, MPH, discusses the importance of hepatitis C virus testing, as it is the first step in the management and treatment of HCV infection.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.64 MB
| Date posted: 7/9/2009
|
Initial HCV Management, Treatment and Monitoring
|
Program Director: Bruce R. Bacon, MD
- John G. McHutchison, MD, FRACP
|
|
|
John McHutchison, MD, FRACP, provides an overview of the AASLD 2009 guideline update on the initial management, treatment, and monitoring of patients with hepatitis C.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recount the characteristics of patients for whom HCV treatment is generally accepted and those for whom the decision must be individualized or is contraindicated
- Discuss factors associated with response and nonresponse in hepatitis C
- Explain how treatment modifications for HCV-infected patients may increase SVR rates
- Recall which strategies are recommended for the management of treatment-related adverse events
|
Slideset: Initial HCV Management, Treatment and Monitoring
 |
|
In this downloadable slideset, John G. McHutchison, MD, FRACP, provides an update on the initial management, treatment, and monitoring of patients with hepatitis C.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.39 MB
| Date posted: 9/11/2009
|
Management and Treatment of Special Populations of HCV-Infected Patients
|
Program Director: Bruce R. Bacon, MD
|
|
Ira M. Jacobson, MD, reviews the AASLD guideline recommendations for the treatment of special populations of HCV-infected persons.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss how normal alanine aminotransferase levels, cirrhosis, intravenous drug use, and previous nonresponse may impact response to peginterferon plus ribavirin therapy
- Recall peginterferon and ribavirin dosing recommendations for HCV-infected children and black patients
- Compare and contrast the benefits and risks of delaying treatment for acute HCV infection
- Recall whether patients receiving solid organ transplantations should be considered for HCV therapy
- Discuss how the medical management of comorbidities such as HIV coinfection, kidney disease, and psychiatric disorders may affect and be affected by hepatitis C treatment
|
Slideset: Management and Treatment of Special Populations of HCV-Infected Patients
 |
|
In this downloadable slideset, Ira M. Jacobson, MD, reviews the AASLD guideline recommendations for the treatment of special populations of HCV-infected persons.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.29 MB
| Date posted: 10/6/2009
|
Interactive Case Challenges
Management of a Genotype 1 HCV Patient in a Methadone Maintenance Program
|
Program Director: Bruce R. Bacon, MD
|
|
David R. Nelson, MD, discusses management strategies and AASLD recommendations involved in managing a treatment-naive genotype 1 HCV–infected patient who is participating in a methadone maintenance program
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify and individualize HCV therapy based on pretreatment factors predictive of response to HCV therapy
- Assess the impact of viral kinetics and treatment duration on achieving a sustained virologic response
- Recount management strategies for adverse events related to HCV therapy
|
Management of an HCV-Infected Compensated Cirrhotic Patient With Moderate Alcohol Use
|
Program Director: Bruce R. Bacon, MD
|
|
Guy Neff, MD, MBA, discusses the challenging management decisions involved in treating an HCV-infected compensated cirrhotic patient with moderate alcohol use.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Distinguish compensated cirrhosis from decompensated cirrhosis based on laboratory values and available algorithms
- Define appropriate treatment strategies for compensated and decompensated cirrhotic patients
- Apply appropriate management strategies for HCV-infected cirrhotic patients who use alcohol
|
Management of an HCV-Infected Black Woman With Delayed Diagnosis and Treatment
|
Program Director: Bruce R. Bacon, MD
- Maribel Rodriguez-Torres, MD, CPI
|
|
|
Maribel Rodriguez-Torres, MD, CPI, discusses the management of an HCV-infected black woman with significant liver disease due to delayed diagnosis and treatment.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recall the barriers to treatment among minority populations infected with hepatitis C
- Summarize and apply appropriate management strategies for an HCV-infected black patient
- Describe characteristics of black and Latino patients that may explain the low response rates to hepatitis C therapy
|
Initial HCV Therapy in a Patient With Mild Depression
|
Program Director: Bruce R. Bacon, MD
|
|
K. Rajender Reddy, MD, discusses optimal treatment strategies for a patient with chronic HCV infection and a history of depression.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify pretreatment risk factors for the development of adverse events associated with hepatitis C virus therapy
- Assess the impact of viral kinetics on treatment duration modification
- Apply strategies for evaluating and managing fatigue and depression in patients with depressive symptoms during hepatitis C virus therapy
|
HCV Treatment Candidacy in an HCV/HIV-Coinfected Patient Receiving HIV Therapy
|
Program Director: Bruce R. Bacon, MD
|
|
Norbert Bräu, MD, reviews the management of HCV in a patient coinfected with HIV.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recall the guidelines for HCV treatment candidacy in patients coinfected with HIV
- Assess the considerations for choosing antiretrovirals in HIV patients receiving HCV therapy
- Review the management of interferon-induced neutropenia in HIV patients receiving HCV therapy
- Describe the importance of CD4+ cell count and percentage in HIV patients receiving HCV therapy
|
Retreatment in a Patient Failing Initial HCV Therapy
|
Program Director: Bruce R. Bacon, MD
|
|
Samuel B. Ho, MD, presents a case patient who showed an initial response to peginterferon/ribavirin therapy but did not achieve sustained virologic response.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Review fixed and modifiable factors that may contribute to nonresponse to HCV therapy
- Recall the guidelines for determining HCV retreatment candidacy
- Describe strategies for retreatment in HCV patients failing initial HCV therapy
|
Downloadable Worksheet
|
HCV Management Algorithm Based on the 2009 AASLD Practice Guideline “Diagnosis, Management, and Treatment of Hepatitis C: An Update"
 |
This quick reference guide to the AASLD HCV Practice Guideline Update condenses the recommendations into a concise chronic HCV infection treatment algorithm. |
|
 |
Download Worksheet |
Partnership Information
|
|
|
|
This program is produced in collaboration with the AASLD. For more information about the AASLD, go to http://www.aasld.org
To view the AASLD 2009 Practice Guidelines*, click on the following link.
*The AASLD 2009 Practice Guidelines were developed solely by AASLD without industry funding or influence. |
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME/CE-certified components of this program.
|